Fennec CEO acquires 1,159 shares from award

FENNEC PHARMACEUTICALS INC.

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. Chief Executive Officer Jeffrey S. Hackman reported acquiring 1,159 common shares through the exercise or conversion of a derivative award. A footnote explains these shares were released from restriction from shares awarded on 3/28/2025.

After this transaction, Hackman directly holds 61,666 common shares. The filing reflects a routine compensation-related release of previously granted equity rather than an open-market purchase or sale.

Insider Trade Summary

Exercise: 1,159 shares

Exercise 1 txn

Insider Hackman Jeffrey S.

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Exercise	Common Shares	1,159	$0.00	$0.00

Holdings After Transaction: Common Shares — 61,666 shares (Direct)

Footnotes (1)

1. F1. Represents shares released from restriction from shares awarded 3/28/2025.

Key Figures

Shares acquired: 1,159 shares Price per share: $0.00 per share Post-transaction holdings: 61,666 shares

3 metrics

Shares acquired 1,159 shares Common Shares acquired via derivative exercise/conversion on April 30, 2026

Price per share $0.00 per share Reported transaction price for 1,159 Common Shares

Post-transaction holdings 61,666 shares Common Shares directly owned by Jeffrey S. Hackman after transaction

Key Terms

Exercise or conversion of derivative security, Common Shares, shares released from restriction

3 terms

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

Common Shares financial

"security_title: Common Shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

shares released from restriction financial

"Represents shares released from restriction from shares awarded 3/28/2025."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did FENNEC (FENC) CEO Jeffrey Hackman report in this Form 4?

Jeffrey S. Hackman reported acquiring 1,159 Fennec common shares. The shares came from the exercise or conversion of a prior equity award, not from an open-market trade. This increased his directly held stake as reflected in the filing.

How many FENNEC (FENC) shares does the CEO hold after this transaction?

After the transaction, CEO Jeffrey S. Hackman directly holds 61,666 common shares. This figure reflects his updated ownership following the 1,159-share acquisition from the release of restrictions on a previously granted award.

Was the FENNEC (FENC) CEO’s Form 4 transaction an open-market buy or sell?

The Form 4 does not show an open-market buy or sell. Instead, it records the acquisition of 1,159 common shares through exercise or conversion of a derivative award, tied to shares previously awarded and later released from restriction.

What does the footnote in Jeffrey Hackman’s FENNEC (FENC) Form 4 explain?

The footnote states the 1,159 shares represent shares released from restriction from shares awarded on 3/28/2025. This clarifies that the transaction reflects vesting or release of a prior equity grant rather than a new market purchase.

How large is the FENNEC (FENC) CEO’s latest equity award release?

The reported release covers 1,159 common shares. These shares stem from a previously granted award that became unrestricted, modestly increasing CEO Jeffrey S. Hackman’s directly held position as disclosed in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/01/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hackman Jeffrey S.

(Last) (First) (Middle)

68 TW ALEXANDER DRIVE

PO BOX 13628

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares(1)	04/30/2026		M		1,159	A	$0	61,666	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares released from restriction from shares awarded 3/28/2025.

	/s/ Jeffrey Hackman	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)